# **EXHIBIT 4**

# UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

In re: NEXIUM (ESOMEPRAZOLE) ANTITRUST LITIGATION MDL No. 2409

Civil Action No. 1:12-md-02409-WGY

This Document Relates To:

All Actions

# DECLARATION OF THOMAS M. SOBOL IN SUPPORT OF PLAINTIFFS' MOTION FOR REIMBURSEMENT OF EXPENSES AND <u>CREATION OF A FUND FOR FUTURE LITIGATION EXPENSES</u>

I, Thomas M. Sobol, declare as follows:

1. I am a member of the bar of the Supreme Judicial Court of the Commonwealth of Massachusetts and of the United States District Court for the District of Massachusetts. I am a partner at the law firm of Hagens Berman Sobol Shapiro LLP. I submit this declaration in support of Plaintiffs' Motion for Reimbursement of Expenses in connection with services rendered in prosecuting this action through trial. This declaration addresses the expenses of my office only. A separate declaration addresses the common expenses paid out of the Direct Purchaser Plaintiffs' litigation fund.

2. My firm has acted as counsel to the direct purchaser class plaintiffs in this litigation. During the course of this litigation, my firm has been involved in all activities, soup to nuts, including:

- investigation of facts,
- legal research and drafting memoranda of law,
- discovery, including reviewing documents; producing documents, and addressing discovery disputes,
- preparing expert witnesses for and/or taking and defending 10 depositions,
- conferring with experts concerning preparation of reports, and
- court appearances, including serving as trial counsel.

#### Case 1:12-md-02409-WGY Document 1582-4 Filed 09/28/15 Page 3 of 4

3. The total number of hours expended by my firm from inception of the litigation through November 24, 2014, the date on which the settlement with Teva was agreed to in principal, is 20,020.10 hours, which includes 16,553.62 attorney hours and 3,466.48 hours spent by paralegals. My firm spent an additional 4.5 hours of attorney time finalizing the Teva settlement agreement and addressing notice and administrative issues related to the Teva settlement.

4. My firm has incurred a total of \$763,225.42 in non-reimbursed expenses, including litigation fund contributions, in connection with the prosecution of this litigation through the end of trial, including return travel from trial. These expenses are summarized as follows:

EXPENSE	AMOUNT
Travel/Hotel/Meals	\$ 93,407.90
Copying Services	\$ 12,008.51
Research Services	\$ 17,395.20
Telephone/Teleconference/Fax	\$ 3,863.14
FedEx/Messengers/Postage	\$ 5,032.03
Court Fees	\$ 900.00
Contributions to Litigation Fund	\$ 600,000.00
Other (describe) – IT equipment, court reporter and transcripts, process servers, public relations marketing	\$ 30,648.64
TOTAL	\$ 763,255.42

5. The expenses incurred in this action are reflected on my firm's books and records, which are maintained in the ordinary course of business and prepared from invoices, receipts,

### Case 1:12-md-02409-WGY Document 1582-4 Filed 09/28/15 Page 4 of 4

credit card bills, cancelled checks and wire transfer notices, expense vouchers, check records, and other source materials, and they represent an accurate recordation of the expenses incurred.

6. My firm has substantial experience in pharmaceutical antitrust class action cases. A firm biography and the biography of each attorney currently employed with the firm who has worked on this case are available upon request and on Hagens Berman Sobol Shapiro LLP's website. *See* www.hbsslaw.com.

I declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge, information, and belief.

# HAGENS BERMAN SOBOL SHAPIRO LLP

<u>/s/ Thomas M. Sobol</u> Thomas M. Sobol

Dated: September 8, 2015